T

    Tempest Therapeutics Inc (TPST)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.09
    +0.03 (+2.83%)

    Market Cap: $17.53M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -48.78%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.35 - $-0.35
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-0.35
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.41
    Range$-0.41 - $-0.41
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.41---
    Sep 26EST
    		-$-0.35---
    Jun 26
    		$-0.34$-0.30-13.33%Miss+83.6%
    Mar 26
    		$-0.50$-0.28-79.96%Miss+84.1%
    Dec 25
    		$-0.62$-0.62+0.00%Beat-100.0%
    Sep 25
    		$-0.79N/A+75.84%Beat+85.2%
    Jun 25
    		$-2.07$-3.23+35.91%Beat+62.1%
    Mar 25
    		$-3.16$-3.29+3.95%Beat+32.5%
    Dec 24
    		$-0.31$-0.24-26.53%Miss+18.4%
    Sep 24
    		$-5.33$-4.58-16.38%Miss+14.6%
    Jun 24
    		$-5.46$-5.33-2.44%Miss+22.2%
    Mar 24
    		$-4.68$-4.94+5.26%Beat+34.5%
    Dec 23
    		$-0.38$-0.39+2.56%Beat+39.7%
    Sep 23
    		$-6.24$-7.19+13.21%Beat+27.3%
    Jun 23
    		$-7.02$-7.54+6.90%Beat+31.6%
    Mar 23
    		$-7.15$-8.54+16.28%Beat-505.9%
    Dec 22
    		$-0.63$-0.76+17.11%Beat+92.1%
    Sep 22
    		$-8.58$-9.88+13.16%Beat+45.5%
    Jun 22
    		$-10.27$-12.00+14.42%Beat+25.0%
    Mar 22
    		$-1.18$-1.12-5.36%Miss+82.1%
    Dec 21
    		$-7.93N/A+50.53%Beat-35.6%
    Sep 21
    		$-15.73$-13.61-15.58%Miss-208.4%
    Jun 21
    		$-13.69$-11.37-20.40%Miss-63.0%
    Mar 21
    		$-6.60$-5.25-25.71%Miss+32.3%
    Dec 20
    		$-5.85$-5.15-13.59%Miss+55.2%
    Sep 20
    		$-5.10$-6.90+26.09%Beat+60.9%
    Jun 20
    		$-8.40$-8.20-2.44%Miss+24.3%
    Mar 20
    		$-9.75$-10.00+2.50%Beat+16.7%
    Dec 19
    		$-13.05$-12.18-7.14%Miss-6.1%
    Sep 19
    		$-13.05$-12.38-5.41%Miss-1551.9%
    Jun 19
    		$-11.10$-12.12+8.42%Beat-236.4%
    Mar 19
    		$-11.70$-10.55-10.90%Miss-271.4%
    Dec 18
    		$-12.30$-12.85+4.28%Beat+77.2%
    Sep 18
    		$-0.79N/A+80.49%Beat+98.6%
    Jun 18
    		$-3.30$-0.27-1122.22%Miss+97.1%
    Mar 18
    		$-3.15$-0.28-1025.00%Miss+96.3%
    Dec 17
    		$-54.00$-61.95+12.83%Beat+51.0%
    Sep 17
    		$-58.50$-89.78+34.84%Beat+51.9%
    Jun 17
    		$-114.75$-94.33-21.65%Miss-
    Mar 17
    		$-85.50$-95.96+10.90%Beat-
    Dec 16
    		$-110.25$-129.94+15.15%Beat-
    Sep 16
    		$-121.50$-138.37+12.19%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.48EV/EBITDA0.31x
    Price/FCF-0.80xFCF Yield-124.92%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-931.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.38xQuick Ratio0.38x
    Trading Statistics
    Beta-1.68Avg Volume275.01K
    52-Week High$12.2352-Week Low$0.84

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.07
    SMA 20$1.05
    SMA 50$1.03
    SMA 200$2.16
    EMA 10$1.07
    EMA 20$1.06
    EMA 50$1.12
    EMA 200$2.68

    MACD

    Line: 0.02Signal: 0.01Hist: 0.00

    ADX

    ADX: 19.5+DI: 19.9-DI: 17.3

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down8.0
    PSAR$1.03

    Bollinger Bands

    Upper Band$1.24
    Lower Band$0.87
    %B Position3483%(Upper)
    Band Width0.60

    RSI (14-Day)

    Neutral
    53.5

    Momentum Oscillators

    Stoch %K35.7
    Stoch %D41.8
    Williams %R-61.0
    ROC (10d)-3.5%
    Momentum-0.04
    CCI (20d)35.4
    MFI (14d)56.3

    Volatility Measures

    ATR (14d)$0.08(7.4%)
    StdDev (20d)0.09
    Hist Vol101.2%(High)

    Volume Flow

    VWAP$1.09
    OBV-4.3M
    AD Line6.2B
    CMF (20d)0.138

    Volume Metrics

    Avg Vol (20d)283.5K
    Vol Ratio0.2x(Low)
    VWMA (20d)$1.11

    Pivot Points

    R3$1.15
    R2$1.13
    R1$1.09
    Pivot Point$1.07
    S1$1.03
    S2$1.01
    S3$0.97

    Advanced Oscillators

    TSI5.45
    Ultimate Osc50.2
    KST126.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$486,000$0$0$0$0$0
    Cost of Revenue$0$0$65,000$0$0$0$243,000$0$0$0$85,000$0
    Gross Profit$0$0$-65,000$0$0$0$243,000$0$0$0$-85,000$0
    Operating Expenses$5.25M$27.72M$4.08M$3.60M$7.97M$10.94M$13.92M$10.55M$9.58M$7.97M$7.51M$6.59M
    R&D$1.82M$22.29M$538,000$570,000$3.87M$7.63M$10.74M$7.56M$5.84M$4.34M$4.18M$4.22M
    SG&A$3.43M$5.42M$3.54M$3.03M$4.09M$3.31M$3.18M$2.99M$3.75M$3.63M$3.33M$2.37M
    Operating Income$-5,250,000$-27,719,000$-4,076,000$-3,597,000$-7,966,000$-10,936,000$-13,919,000$-10,551,000$-9,582,000$-7,974,000$-7,514,000$-6,592,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$46,000$161,000$247,000$329,000$372,000$368,000$377,000$373,000
    Income Before Tax$-5,244,000$-27,696,000$-4,021,000$-3,511,000$-7,870,000$-10,860,000$-13,813,000$-10,556,000$-9,570,000$-7,904,000$-7,488,000$-6,786,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,244,000$-27,696,000$-4,021,000$-3,511,000$-7,870,000$-10,860,000$-13,813,000$-10,556,000$-9,570,000$-7,904,000$-7,488,000$-6,786,000
    EBITDA$-5,184,000$-27,636,000$-3,956,000$-3,445,000$-7,757,000$-10,631,000$-13,517,000$-10,130,000$-9,043,000$-7,448,000$-7,026,000$-6,325,000
    EBIT$-5,244,000$-27,696,000$-4,021,000$-3,511,000$-7,824,000$-10,699,000$-13,566,000$-10,227,000$-9,198,000$-7,536,000$-7,111,000$-6,413,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TPST

    News

    Tempest Therapeutics names Nicholas Rossettos CFO, replacing Justin Trojanowski

    Tempest Therapeutics announced that Justin Trojanowski will resign as principal financial and accounting officer effective September 1, 2026. Nicholas Rossettos will succeed him as CFO, principal financial and accounting officer, treasurer, and corporate secretary on the same date. Rossettos brings extensive experience, having provided CFO consulting services since 2012 and previously holding CFO roles at Egenix and interim positions at Sernova.

    Bitget•8/24/26•
    Neutral

    Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing

    Tempest Therapeutics announced that Justin Trojanowski will resign from his roles as Principal Financial Officer and Principal Accounting Officer. His resignation is effective September 1. This information was disclosed in an SEC filing.

    TradingView•8/24/26•
    Neutral

    Tempest Therapeutics files prospectus for sale of 8.9 million shares

    Tempest Therapeutics has filed a prospectus with the SEC for the sale of up to 8,910,579 shares of common stock, a move aimed at raising capital through an equity offering. This formal disclosure outlines the company's intent for the share distribution but does not specify pricing or final proceeds. The filing is a procedural step for capital raising, following the company's recent Q2 report which showed a narrowed net loss but significantly reduced cash reserves, indicating ongoing needs for capital infusion.

    scanx.trade•8/22/26•
    Neutral

    Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders

    Tempest Therapeutics has filed an S-1 registration statement to offer up to 8,910,579 shares of common stock for resale by Lincoln Park Capital Fund LLC. This agreement could allow Tempest to raise up to $50 million, but the current registration only covers approximately $8.16 million at the last closing price of $1.02 per share, with the rest requiring further registration and stockholder approval beyond a 19.99% Nasdaq Exchange Cap. The company acknowledges potential significant dilution for existing shareholders and warns that the actual proceeds may be substantially less than the $50 million maximum commitment.

    Stock Titan•8/21/26•
    Somewhat-Bearish

    Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com

    This article announces that Tempest Therapeutics Inc. filed a Form 8K on August 18, 2026. The brief piece includes the stock symbol TPST, which showed a -5.31% change. The content primarily serves as a notice of the filing and directs readers to Investing.com for more details.

    Investing.com Nigeria•8/18/26•
    Neutral

    Frequently Asked Questions About TPST

    Does TPST pay dividends?
    Tempest Therapeutics Inc (TPST) does not currently pay a regular dividend.
    What is TPST's market cap?
    Tempest Therapeutics Inc (TPST) has a market capitalization of $17.53M with a current stock price of $1.09.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In